Red Queen Bio has raised $36M to build AI-designed antibody drugs fast enough to outrun whatever frontier models might enable.
HITS, the KAIST spinout, has raised $13.4M to put AI agents that search literature, analyze data and test hypotheses into…
A Boston company working on technology licensed from Mass General Brigham wants AI to connect evidence across entire preclinical safety…
A lab led by attention-mechanism pioneer Kyunghyun Cho has a $500M commitment to build one foundation model spanning biology, clinical…
The Shanghai spinout's first outside round values the young company near $1.5B and keeps ByteDance as its largest shareholder.
The 2026 Prix Galien USA nominees lean heavily into artificial intelligence across digital health and startup categories.